Trial to Evaluate the Therapeutic Benefit of Fulvestrant in Combination With ZACTIMA in Postmenopausal Women With Bone Predominant, Hormone Receptor Positive Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Fulvestrant + ZACTIMA|DRUG: Fulvestrant + Placebo
Sponsor: Ontario Clinical Oncology Group (OCOG)
Collaborators: AstraZeneca